glp-1 osteoarthritis treatment via the GLP-1–mediated gut-joint axis targets intestinal FXR signaling The GLP-1 agonist, liraglutide, ameliorates

p=0.046) was statistically significant but not clinically relevant

Switching from Ozempic to Mounjaro (or back)

Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant weight loss and ACR50 disease control in adults with active psoriatic arthritis (PsA).

Losing weight is challenging but achievable

Objective The aim was to compare the risk of incident AF after initiation of GLP-1RAs versus dipeptidyl peptidase-4 inhibitors (DPP4is), as active comparators, in patients with DM